Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. US20100130424 - CRHR2 peptide agonists and uses thereof

Office
États-Unis d'Amérique
Numéro de la demande 12612548
Date de la demande 04.11.2009
Numéro de publication 20100130424
Date de publication 27.05.2010
Numéro de délivrance 10040838
Date de délivrance 07.08.2018
Type de publication B2
CIB
C07K 14/57
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
52Cytokines; Lymphokines; Interférons
555Interférons (IFN)
57IFN-gamma
A61K 38/00
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
C07K 14/575
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
575Hormones
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/57509
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
57509Corticotropin releasing factor [CRF] (Urotensin)
Déposants Ronald V. Swanson
JANSSEN PHARMACEUTICA NV
Nigel P. Shankley
Veronica Moreno
Peter Gengo
Inventeurs Ronald V. Swanson
Nigel P. Shankley
Veronica Moreno
Peter Gengo
Mandataires Porzio, Bromberg & Newman P.C.
Titre
(EN) CRHR2 peptide agonists and uses thereof
Abrégé
(EN)

The present invention relates to novel peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonist preferably comprise modifications that include pegylated peptides. Furthermore, the present invention also relates to methods for the treatment and prevention of a disease or disorder related to CRHR2 activity.

Related patent documents
NI2012-000085 IThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa201206780This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.